Illumina (ILMN), a leading name in the bio-tech market, is making significant strides. The company's options for
February 2025 have become available, and it's currently enjoying an average
Moderate Buy recommendation from analysts. The company’s stock has showcased some fluctuations, with an
RS rating climbing to 71, showing overall positive momentum.
Illumina acquired Fluent BioSciences, aiming to expand single-cell analysis and discovery to a wider customer base. Third-quarter financial results have been announced for the
fiscal year 2024. The company has a promising outlook as a top momentum stock for the long term despite a
9.3% drop from the last earnings report.
Illumina's Q3 earnings surpassed estimates, whereas it expects to witness significant growth in future earnings. The company continues to strengthen its position by expanding the TruSight Oncology portfolio, with
Charles Dadswell stepping down and a successor search initiated. European Court of Justice has ruled in favor of Illumina in a jurisdictional dispute, and the company now introduces the
MiSeq i100 Series – its simplest, fastest benchtop sequencers.
Illumina ILMN News Analytics from Mon, 20 May 2024 07:00:00 GMT to Thu, 26 Dec 2024 15:57:00 GMT -
Rating 8
- Innovation 5
- Rumor 7
